Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Toni K. Choueiri(Dana-Farber Cancer Institute), Laurence Albigès(Institut Gustave Roussy)
Cited by 457
Related Papers
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136